title: Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study.
abstract: OBJECTIVE
  The long-term evaluation of basiliximab induction therapy has not been addressed yet. We aim to evaluate its long-term effects in living related donor kidney transplantation.
  
  
  METHODS
  100 adult recipients with their first kidney allograft were randomized into two treatment groups--one group received basiliximab and the second served as a control. All patients received a maintenance triple immunosuppressive therapy (steroids, cyclosporine microemulsion and azathioprine) and were closely followed for 5 years.
  
  
  RESULTS
  Basiliximab significantly reduced the proportion of patients who experienced an acute rejection in the first year (18/50) when compared to the control group (31/50) and in 5 years (27/50) when compared to (36/50) the controls. The cumulative steroid dose used throughout the study was significantly lower in the basiliximab group. The overall incidence of post-transplant complications was comparable between the two treatment groups. There was no significant difference in patients and graft survival; 5-year patient and graft survival were 100 and 86% for basiliximab, and 96 and 88% for the control group respectively.
  
  
  CONCLUSIONS
  Although routine basiliximab induction significantly reduces the incidence of acute rejection, its beneficial long-term effects on graft function and patient and graft survival are not yet evident.
authors.affiliation: Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. drhattia@yahoo.com
authors.forename: Hussein A
authors.initials: HA
authors.lastname: Sheashaa
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Bakr
authors.forename: Amany M
authors.initials: AM
authors.lastname: Ismail
authors.forename: Osama E
authors.initials: OE
authors.lastname: Gheith
authors.forename: Khalid F
authors.initials: KF
authors.lastname: El-dahshan
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Sobh
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Ghoneim
mesh_terms: D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D004305:Dose-Response Relationship, Drug; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects; D019520:Living Donors; D008137:Longitudinal Studies; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology; D011446:Prospective Studies; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D013256:Steroids; D000077552:Basiliximab